Tianning Zhang

Dr. Tianning Zhang

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Clinical Lung Cancer
Verified
Journal Article
Closed access
TQTian Qiu
Tian Qiu
WLWeihua Li
Weihua Li
TZTianning Zhang
Tianning Zhang
PXPuyuan Xing
Puyuan Xing
WHWenting Huang
Wenting Huang
JLJunling Li
Junling Li

6 January 2022 in Frontiers of Computer Science
Verified
Journal Article
Closed access
PDF file
TZTianning Zhang
Tianning Zhang
MCMiao Cai
Miao Cai
DZDiming Zhang
Diming Zhang
HHHao Huang
Hao Huang

7 April 2026 in Sensors
Verified
Journal Article
Open access
PDF file
ACAijia Chu
Aijia Chu
TZTianning Zhang
Tianning Zhang
CWChengyi Wang
Chengyi Wang
As a foundational protocol in wireless sensor networks (WSNs), LEACH has long contended with the dual challenges of energy load balancing and security defense. To clarify the protocol’s evolutionary trajectory within the modern IoT context, this paper presents a systematic review and restructuring of LEACH’s optimization mechanisms. The core contributions of this study are threefold: First, it establishes a taxonomy for energy optimization in LEACH. It provides an in-depth analysis of how intelligent algorithms—such as fuzzy logic and meta-heuristics—reshape cluster head election and data transmission paths in heterogeneous network environments, thereby resolving the inherent blindness of traditional mechanisms. Second, it elucidates the evolutionary patterns of LEACH security mechanisms. The paper details the transition of defense strategies from early static encryption and authentication to dynamic countermeasure mechanisms, offering a clear framework for understanding the protocol’s defensive boundaries. Finally, addressing the bottleneck where high security levels often incur high energy costs, the paper explores the feasibility of incorporating zero-trust architecture (ZTA) into WSNs within the future outlook section. This discussion aims to provide a new theoretical perspective for future research on balancing enhanced defense capabilities with energy efficiency.

2 November 2023 in Blood
Verified
Journal Article
Open access
CWChao-Ling Wan
Chao-Ling Wan
YHYuan-Hong Huang
Yuan-Hong Huang
SHSi-Man Huang
Si-Man Huang
TZTianning Zhang
Tianning Zhang
KTKai-Wen Tan
Kai-Wen Tan
SXSheng-Li Xue
Sheng-Li Xue
Background RUNX1 is one of the recurrent mutated genes in newly diagnosed acute myeloid leukemia (AML) with a frequency of 6%~15%. Although historically recognized as a provisional distinct entity, the AML subtype with RUNX1 mutations (AML- RUNX1mut) was eliminated from the 2022 WHO classification system. With the update of AML diagnosis and treatment protocol, different outcomes of AML- RUNX1muthave been reported. However, an in-depth study about the prognostic value of RUNX1 mutations, epecifically the classification change related to AML- RUNX1mut in a large well-annotated cohort is lacking. Methods The clinical data of 1065 AML (excluding acute promyelocytic leukemia and RUNX1 germline mutations) patients according to WHO 2016 and treated from January 2017 to December 2021 at Jiangsu Institute of Hematology were retrospectively collected and analyzed after informed consent. All AML diagnosis samples were analyzed by targeted Next Generation Sequencing (NGS) panel covering 172 frequently mutated genes in hematological malignancies. Demographic and clinical data, disease characteristics at diagnosis, first-line treatment and clinical outcome data were available for all patients. The survival time of allogeneic hematopoietic stem cell transplantation patients was censored at the time of stem cell transfusion. Cytogenetic and molecular characteristics were used to classify patients into ELN2017 and ELN2022 risk groups (excluding the effect of RUNX1 mutation). Results RUNX1 mutations were detected in 112 (10.5%) patients, namely, 66 (58.9%) male and 46 (41.1%) female. A total of 132 RUNX1 alterations were detected with a medianvariant allelic frequency of 40% (3%~93%). RUNX1 mutations were associated with older age (48.5 vs. 46.0 years old, P=0.087) and antecedent myeloid disorders (6.3% vs. 1.0%, P<0.001). One or more comutations were detected in 106 (94.7%) AML- RUNX1mut patients. The most frequent co-gene abnormalities were FLT3-ITD and DNMT3A mutations which represented the 23.2% and 18.7%. Mutations of CEBPA bZIP, NPM1 and translocations of t(8;21), t(16;16)/inv(16) were uncommon in AML- RUNX1mut with a frequency of 6.3%, 1.8%, 2.7%, 0%, respectively (Table 1). Compared with AML with wild-type RUNX1 (AML- RUNX1wt), AML- RUNX1mut patients had a lower complete remission rate (19.6% vs. 29.7%, P=0.034), lower overall response rate (ORR) (73.5% vs. 84.3%, P=0.006) and higher no response rate (26.5% vs. 15.5%, P=0.021) in the first induction chemotherapy. When comparing groups based on the ELN2017 risk stratification criteria, no significant difference in ORR was observed between RUNX1mut and RUNX1wt patients in the favorable (91.2% vs. 94.0%, P=0.572), intermediate (75.0% vs. 78.4%, P=0.570) and adverse (63.3% vs. 71.4%, P=0.370 ) subgroups (Table 2). The median duration of follow-up of the entire cohort was 8.7 months ( RUNX1wt: 8.4 months; RUNX1mut: 10.0 months). Comparing the two groups, patients with RUNX1 mutations had a lower 5-year overall survival (OS) rate (35.4% vs. 42.3%; HR=1.563; 95% CI: 1.091~2.237, P=0.026), but no significant difference was observed in the 5-year event-free survival (EFS) rate (40.8% vs. 35.4%; HR=1.084; 95% CI: 0.750~1.570, P=0.098) (Table 2). However, when patients were stratified according to the ELN2017 guidelines (excluding the effect of RUNX1 mutation), outcomes did not differ between patients withor without RUNX1 mutation in the favorable (OS: P=0.629, EFS: P=0.137), intermediate (OS: P=0.629, EFS: P=0.114) and adverse (OS: P=0.544; EFS: P=0.714) subgroups. Similar results were obtained according to the ELN2022 guidelines. In multivariate analysis, RUNX1 was not an independent prognostic factor for OS (HR=1.353, 95% CI: 0.922~1.985, P=0.122) and EFS (HR=1.422, 95% CI: 0.975~2.075, P=0.068), while significantly worse OS and EFS were observed in patients with mutated FLT3-ITD, TP53, and DNMT3A ( P-values were all less than 0.05). Conclusion RUNX1 mutations were rarely isolated genetic abnormities that conferred inferior outcomes. However, on the basis of ELN prognosis risk stratification, RUNX1mutation had no impact on the clinical outcomes of AML patients in stratified subgroups. RUNX1 was not an independent prognostic factor for survival. Overall, our findings agree with the updated WHO classification system for AML that AML- RUNX1mut should not be recognized as a distinct AML entity.

4 February 2023
Verified
Book Chapter
Closed access
PDF file
TZTianning Zhang
Tianning Zhang
MCMiao Cai
Miao Cai
DZDiming Zhang
Diming Zhang
HHHao Huang
Hao Huang

2 August 2026
Verified
Book Chapter
Closed access
PDF file
CMCao Mengru
Cao Mengru
TZTianning Zhang
Tianning Zhang
ZRZhang Renyu
Zhang Renyu
WDWang Dong
Wang Dong